HCW Biologics is trading at $1.10, down 5.14%, amid a broader risk-off session. - Technology shares faced pressure from AI-spending concerns, while rising oil prices added to market unease. Reuters reported the Nasdaq slid more than 2% as concerns weighed on growth stocks. - No new company-specific announcement was identified for October 22. The latest company release, dated October 9, concerned preparation of an IND application for its lead T-cell engager.